

Personal Information

Name: Joan Seoane
Address: Vall d'Hebron Institute of Oncology (VHIO)
Vall d'Hebron University Hospital
c/ Natzaret 115-117
08035 - Barcelona, Spain
Phone: +34 93 254 34 50 ext. 8641
E-mail: jseoane@vhio.net

Education

1989-1993: B.Sc. Chemistry, University of Barcelona, Barcelona, Spain.

Jul-Sep 1991: Student researcher, Boehringer Ingelheim, Malgrat, Spain. Director of the project: C. von Carsten, Ph.D.

Jul-Nov 1993: Student researcher, Boehringer Ingelheim, Ingelheim, Germany. Director of the project: C. Naumann, Ph.D.

1994-1998: Ph.D. Student in Chemistry, Dept. Biochemistry and Molecular Biology, University of Barcelona (UB), Barcelona, Spain.

Jul-Sep 1997: Short stay at laboratory of C.B. Newgard, Ph.D., Professor, Dept. of Biochemistry and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.

17th Apr 1998: Ph.D. in Chemistry, Program of Biochemistry, University of Barcelona (UB), Dept. Biochemistry and Molecular Biology. Barcelona, Spain.

1st May - 5th Jun 1998: Short stay at laboratory of Lorraine Agius, Ph.D., Reader in Biochemistry, University of Newcastle upon Tyne, Dept. of Medicine, Newcastle, UK.

15th Jul 1998-15th Jul 2001: Research Fellow, Memorial Sloan-Kettering Cancer Center, New York.

15th Jul 2001- Dec 2003: Research Associate, Memorial Sloan-Kettering Cancer Center, New York.

Jan 2004-present: ICREA Research Professor, Group Leader, Medical Oncology Program, Vall d'Hebron University Hospital, Barcelona, Spain.

Sep 2006-present: Member of the Neuro-Oncology Committee. Vall d'Hebron Hospital, Barcelona, Spain.

Oct 2007: EMBO (European Molecular Biology Organization) Young Investigator.

Apr 2008-present: Group Leader, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain.

Sep 2008-present: Associate Professor, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

Sep 2008-2012: Coordinator Spanish National Agency of Grant Evaluation (ANEP).

Oct 2008-present: Board Member of the European Association for Cancer Research (EACR).

Jan 2010-present: Member of the Executive Committee, VHIO, Barcelona, Spain.

Jun 2011-present: Director, Translational Research Program, VHIO, Barcelona, Spain.

May 2012: co-Founder and Chairman of Mosaic Biomedicals S.L.U. A VHIO and ICREA Spin-off Biotech Company.

Jan 2015-2019: Associate Coordinator Instituto de Salud Carlos III (FIS) Grant Evaluation panel.

Jan 2015-present: Faculty member of the European Society for Medical Oncology (ESMO).

Jul 2016-present: Secretary General of the European Association for Cancer Research (EACR).

Oct 2017: Fellow of the European Academy of Cancer Sciences (EACS).

Dec 2017-present: Board Member of the Asociación Española contra el Cáncer (AECC).

Feb 2019-2022: Member of the Bosarge Family Foundation-Waun Ki Hong Scholar Award for Regenerative Cancer Medicine Scientific Review Committee (from the AACR)

May 2019- present: Director, co-Preclinical and Translational Research Program, VHIO, Barcelona, Spain.

Awards

Grantor: La Vanguardia & Fundació Catalunya La Pedrera
Premio Vanguardia de la Ciencia | *April 2016*

Grantor: Fundación para la Investigación del Cáncer de la Universidad de Salamanca (FICUS) y Centro de Investigación del Cáncer (CIC)
IV Premio Nacional Doctores Diz Pintado | *January 2015*

Grantor: The Dr. Josef Steiner Cancer Research Foundation
Dr. Josef Steiner Cancer Research Award 2013 | *April 2013*

Grantor: Sociedad Española de Bioquímica y Biología Molecular
Beckman-Coulter Award | *September 2009*

Grantor: Banco Sabadell
Biomedical Research Award | *July 2009*

Grantor: European Molecular Biology Organization (EMBO)
EMBO Young Investigator | *October 2007*

Grantor: Societat Catalana de Biologia
Josep M. Sala Trepat Award | *July 2004*

Grantor: Memorial Sloan-Kettering Cancer Center
MSKCC Research Fellow Award | *April 2003*

Publication List

Rubio-Perez C, Planas-Rigol E, Trincado JL, Bonfill-Teixidor E, Arias A, Marchese D, Moutinho C, Serna G, Pedrosa L, Iurlaro R, Martínez-Ricarte F, Escudero L, Cordero E, Cicuendez M, Ruiz S, Parra G, Nuciforo P, Gonzalez J, Pineda E, Sahuquillo J, Tabernero J, Heyn H*, **Seoane J***. Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. **Nature Communications**. 2021. 12(1):1503.

- Milena Cribiù F, Erra R, Pugni L, Rubio Perez C, Alonso L, Simonetti S, Croci GA, Serna G, Ronchi A, Pietrasanta C, Lunghi G, Fagnani AM, Pinana M, Matter M, Tzankov A, Terracciano L, Anton Pagarolas A, Ferrazzi E, Ferrero S, Iurlaro E, **Seoane J***, Nuciforo P*. Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission. (*co-corresponding authors). **Journal of Clinical Investigation**. 2021. 145427. (Epub ahead of print).
- Bobillo S, Crespo M, Escudero L, Mayor R, Raheja P, Carpio C, Rubio-Perez C, Tazón-Vega B, Palacio C, Carabia J, Jiménez I, Nieto JC, Montoro J, Martínez-Ricarte F, Castellví J, Simó M, Puigdefàbregas L, Abrisqueta P, Bosch F, **Seoane J**. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. **Haematologica**. 2021. 106(2):513-521.
- Puyol M, **Seoane J**, Aguilar E, Voza LB, Orbe I, Crawford KH, Fernández A, Bray F, Johnson SE, Gopal S. WORLD CANCER RESEARCH DAY: A call to action for a coordinated international research effort to prevent, diagnose and treat cancer. **Clinical Cancer Research**. 2021. 27(4):963-966.
- Ligero Hernández M, Garcia Ruiz A, Viaplana C, Villacampa Javierre G, Raciti MV, Landa J, Matos I, Martin Liberal JJ, Ochoa de Olza M, Hierro C, Mateo J, Gonzalez Rodriguez M, Morales R, Suárez C, Rodon J, Élez E, Braña I, Muñoz Couselo E, Oaknin A, Fasani R, Nuciforo P, Gil D, Rubio-Pérez C, **Seoane J**, Felip E, Escobar M, Tabernero J, Carles J, Dienstmann R, Garralda E, Perez Lopez R. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. **Radiology**. 2021. 200928 (Epub ahead of print).
- Galson JD, Schaetzle S, Bashford-Rogers RJM, Raybould MIJ, Kovaltsuk A, Kilpatrick GJ, Minter R, Finch DK, Dias J, James LK, Thomas G, Jason Lee WY, Betley J, Cavlan O, Leech A, Deane CM, **Seoane J**, Caldas C, Pennington DJ, Pfeffer PE, Osbourn J. Deep sequencing of B cell receptor repertoires from COVID-19 patients reveals strong convergent immune signatures. **Frontiers in Immunology**. 2020; 11:605170.
- Escudero L, Martínez-Ricarte F, **Seoane J**. Cerebrospinal fluid circulating tumour DNA as a liquid biopsy for central nervous system malignancies. **Current Opinion Neurology**. 2020; 33(6):736-741.
- Escudero L, Llorca A, Arias A, Diaz-Navarro A, Martínez-Ricarte F, Rubio-Perez C, Mayor R, Caratú G, Martínez-Sáez E, Vázquez-Méndez É, Lesende-Rodríguez I, Hladun R, Gros L, Ramón y Cajal S, Poca M, Puente X, Sahuquillo J, Gallego S, Seoane J. Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma. **Nature Communications**. 2020; 11(1):5376.
- Jiménez, I, Carabia J, Bobillo S, Palacio C, Abrisqueta P, Pagès C, Nieto JC, Castellví J, Martínez-Ricarte F, Escoda L, Perla C, Céspedes-Torrez DH, Boix J, Purroy N, Puigdefàbregas L, **Seoane J**, Bosch F, Crespo M. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition. **Journal of Neuro-Oncology**. 2020; 149(1):13-25.
- Ciardello D, Elez ME, Tabernero J, **Seoane J**. Clinical development of therapies targeting TGFβ: current knowledge and future perspectives. **Annals of Oncology**. 2020. 31 (10):1336 – 1349.
- Le Rhun E, **Seoane J**, Salzet M, Soffiatti R, Weller M. Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. **Cancer letters**. 2020; 480:24-28.
- Seoane J**. Immunotherapy Research: today's science is tomorrow's medicine. **The Innovation Platform**. 2020; 1: 122-123.
- Gargini R*, Segura-Collar B*, Herránz B, Garcia-Escudero V, Romero-Bravo A, Núñez FJ, García-Pérez D, Gutiérrez-Guamán J, Ayuso-Sacido A, **Seoane J**, Pérez-Núñez A, Sepúlveda-Sánchez JM, Hernández-Laín A, Castro MG, García-Escudero R, Ávila J, Sánchez-Gómez P. The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas. **Science Translational Medicine**. 2020; 12(527)

Janin M, Ortiz-Barahona V, de Moura MC, Martínez-Cardús A, Llinàs-Arias P, Soler M, Nachmani D, Pelletier J, Schumann U, Calleja-Cervantes ME, Moran S, Guil S, Bueno-Costa A, Piñeyro D, Perez-Salvia M, Rosselló-Tortella M, Piqué L, Bech-Serra JJ, De La Torre C, Vidal A, Martínez-Iniesta M, Martín-Tejera JF, Villanueva A, Arias A, Cuartas I, Aransay AM, La Madrid AM, Carcaboso AM, Santa-Maria V, Mora J, Fernandez AF, Fraga MF, Aldecoa I, Pedrosa L, Graus F, Vidal N, Martínez-Soler F, Tortosa A, Carrato C, Balañá C, Boudreau MW, Hergenrother PJ, Kötter P, Entian KD, Hench J, Frank S, Mansouri S, Zadeh G, Dans PD, Orozco M, Thomas G, Blanco S, **Seoane J**, Preiss T, Pandolfi PP, Esteller M. Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program. **Acta Neuropathologica**. 2019;138(6):1053-1074.

Seoane J. Beyond blood with liquid biopsies. **ESMO Perspectives**. 2019 August 30.

Siravegna G, Mussolin B, Venesio T, Marsoni S, **Seoane J**, Dive C, Papadopoulos N, Kopetz S, Corcoran R. B, Siu L. L, and Bardelli A. How liquid biopsies can change clinical practice in oncology. **Annals of Oncology**. 2019; 30(10):1580-1590.

Pascual-García M*, Bonfill-Teixidor E*, Planas-Rigol E, Rubio-Pérez C, Iurlaro R, Arias A, Cuartas I, Sala-Hojman A, Escudero E, Martínez-Ricarte F, Huber-Ruano I, Nuciforo P, Pedrosa L, Marques C, Braña I, Garralda E, Vieito M, Squatrito M, Pineda E, Graus F, Espejo C, Sahuquillo J, Tabernero J, **Seoane J**. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing the response to anti-PD1 therapy. (*Equal contributing authors). **Nature Communications**. 2019; 10(1):2416.

De Mattos-Arruda L, Sammut SJ, Ross E, Bashford-Rogers R, Greenstein E, Contente-Cuomo T, Morganella S, Teng Y, Maruvka Y, Pereira B, Rueda O, Chin SF, Ali R, Cope W, Tiezzi D, Markus H, Mayor R, Arias A, Reshef D, Martinez E, Peg V, Ramon y Cajal S, Cortes J, Vassiliou G, Getz G, Nik-Zainal S, Murtaza M, Friedman N, Markowitz F, **Seoane J***, Caldas C*. The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer. (*co-corresponding authors). **Cell Reports**. 2019; 27(9):2690-2708.

Seoane J, De Mattos-Arruda L, Le Rhun E, Bardelli A, Weller M. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and brain metastases. **Annals of Oncology**. 2019; 30(2):211-218.

Rius Ruiz I, Vicario R, Morancho B, Morales CB, Arenas EJ, Herter S, Freimoser-Grundschober A, Somandin J, Sam J, Ast O, Barriocanal ÁM, Luque A, Escorihuela M, Varela I, Cuartas I, Nuciforo P, Fasani R, Peg V, Rubio I, Cortés J, Serra V, Escrivá-de-Romani S, Sperinde J, Chenna A, Huang W, Winslow J, Albanell J, **Seoane J**, Scaltriti M, Baselga J, Tabernero J, Umana P, Bacac M, Saura C, Klein C, Arribas J. p95HER2-T cell bispecific antibody for breast cancer treatment. **Science Translational Medicine**. 2018; 10(461).

Puig I, Tenbaum SP, Chicote I, Arques O, Martínez-Quintanilla J, Cuesta-Borrás E, Ramírez L, Gonzalo P, Soto A, Aguilar S, Eguizabal C, Caratu G, Prat A, Argilés G, Landolfi S, Casanovas O, Serra V, Villanueva A, Arroyo A, Terracciano L, Nuciforo P, **Seoane J**, Recio JA, Vivancos A, Dienstmann R, Tabernero J, Palmer HG. TET2 Controls Chemoresistant Slow-Cycling Cancer Cells Survival and Tumour Recurrence. **Journal of Clinical Investigation**. 2018; 128(9):3887-3905.

Liu Q, Ma L, Jones T, Palomero L, Pujana MA, Martinez-Ruiz H, Ha P, Murnane J, Cuartas I, **Seoane J**, Baumann M, Linge A, Barcellos-Hoff MH. Subjugation of Tgfβ signaling by human papilloma virus in head and neck squamous cell carcinoma shifts DNA repair from homologous recombination to alternative end joining. **Clinical Cancer Research**. 2018; 24(23): 6001-6014

Seoane J; Capdevila J. The right compound for the right target: tackling RET. **Annals of Oncology**. 2018; 29(8):1623-1625.

Martínez-Ricarte F., Mayor R., Martínez-Sáez E., Rubio-Pérez C., Pineda E., Cordero E., Cicuéndez M., Poca MA., López-Bigas N., Ramon y Cajal S., Vieito M., Carles J., Tabernero J., Vivancos A., Gallego S., Graus F.,

- Sahuquillo J., **Seoane J.** Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumour DNA from cerebrospinal fluid. **Clinical Cancer Research**. 2018; 24(12):2812-2819
- Capdevila J, Mayor R, Mancuso FF, Iglesias C, Caratù G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez 4, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, **Seoane J.** Early evolutionary divergence between papillary and anaplastic thyroid cancers. **Annals of Oncology**. 2018; 29(6): 1454–1460
- De Mattos-Arruda L, Ng CKY, Piscuoglio S, Gonzalez-Cao M, Lim RS, De Filippo MR, Fusco N, Schultheis AM, Ortiz C, Viteri S, Arias A, Macedo GS, Oliveira M, Gomez P, Teixidó C, Nuciforo P, Peg V, Saura C, Ramon Y Cajal S, Casas FT, Weigelt B, Cortes J, **Seoane J,** Reis-Filho JS. Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. **Oncotarget**. 2018; 9(29):20617-20630
- Yates L. R., **Seoane J.,** Le Tourneau C., Siu L.L., Marais R., Michiels S., Soria J.C., Campbell P., Normanno N., Scarpa A., Reis-Filho J., Rodon J., Swanton C., Andre F. The European Society of Medical Oncology (ESMO) Precision Medicine Glossary. **Annals of Oncology**. 2018; 29(1):30-35
- Seoane J.** Cancer Division hierarchy leads to cell heterogeneity. **Nature**. 2017; 549(7671):164-166.
- Huber-Ruano I, Raventos C, Cuartas I, Sánchez-Jaro C, Wosikowski K, Janicot M, **Seoane J.** An antisense oligonucleotide targeting TGF- β 2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages. **Annals of Oncology**. 2017; 28(9):2278-2285.
- Gonzalez-Cao M, Berrocal A, Puig S, Karachaliou N, De Matos-Arruda L, **Seoane J,** Escors D, Alvarez C, Vaque J P, Prat A, Wellbrock C, Arozarena I, Marquez-Rodas I, Espinosa E, Molina M A, Puertolas T, Juan-Otero M, Malagrida R, Jantus-Lewintre E, Soriano V, Arance A, Manzano J L, Lorigan P, Gajewski T F, Rosell R, Martin-Algarra S; On behalf of the Spanish Melanoma Group (GEM) Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). **Annals of Translational Medicine** 2017; 5(19):390.
- Seoane J.,** Gomis RR. TGF β Family Signaling in Tumor Suppression and Cancer Progression. **Cold Spring Harbor Perspectives in Biology**. 2017; 9 (12)
- Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, **Seoane J,** Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. Interrogating open issues in cancer precision medicine with patient-derived xenografts. **Nature Reviews Cancer**. 2017; 17(4):254-268.
- Gueorguieva I, Cleverly A, Desai D, Azaro A, Seoane J, Braña I, Sicart E, Miles C, Lahn MM, Mitchell MI, Rodon J. Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer. **Drugs in Context**. 2016; 5: 201303.
- Seoane J.** The Taming of the TAMs. **Trends in Cell Biology**. 2016;26(8):562-3.
- De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramon y Cajal S, Carles J, Rodon J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, **Seoane J.** Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. **Nature Communications**. 2015; 6:8839.

- De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-García J, Masci G, Corsi F, Cortés J, **Seoane J**, Calin GA, Santarpia L. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. **Oncotarget**. 2015;6(35):37269-80.
- Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, **Seoane J**, Martínez-Saez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG 2nd, Gill CM, Van Hummelen P, Thorner AR, Johnson BE, Hoang MP, Choueiri TK, Signoretti S, Sougnez C, Rabin MS, Lin NU, Winer EP, Stemmer-Rachamimov A, Meyerson M, Garraway L, Gabriel S, Lander ES, Beroukheim R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. **Cancer Discovery**. 2015;5(11):1164-77
- Iyengar PV, Jaynes P, Rodon L, Lama D, Law KP, Lim YP, Verma C, **Seoane J**, Eichhorn PJ. USP15 regulates SMURF2 kinetics through C-lobe mediated deubiquitination. **Scientific Reports**. 2015; 5:14733.
- Ulloa F, González-Juncà A, Meffre D, Barrecheguren PJ, Martínez-Mármol R, Pazos I, Olivé N, Cotrufo T, **Seoane J**, Soriano E. Blockade of the SNARE Protein Syntaxin 1 Inhibits Glioblastoma Tumor Growth. **PLoS One**. 2015;10(3):e0119707.
- Rodon J, Carducci MA, Sepulveda-Sanchez JM, Azaro A, Calvo E, **Seoane J**, Brana I, Sicart E, Gueorguieva I, Cleverly AL, Sokalingum Pillay N, Desai D, Estrem ST, Paz-Ares L, Holdoff M, Blakeley J, Lahn MM, Baselga J. First-in-Human Dose Study of the Novel Transforming Growth Factor- β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. **Clinical Cancer Research**. 2015;21(3):553-60.
- Rodon J, Carducci M, Sepulveda-Sánchez JM, Azaro A, Calvo E, **Seoane J**, Braña I, Sicart E, Gueorguieva I, Cleverly A, Pillay NS, Desai D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, Baselga J. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor- β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. **Investigational New Drugs**. 2015;33(2):357-70.
- Seoane J**, De Mattos-Arruda L. Escaping out of the brain. **Cancer Discovery**. 2014;4(11):1259-61.
- Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman S, **Seoane J**, Trusolino L, Villanueva A. Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. **Cancer Discovery**. 2014;4(9):998-1013.
- Henderson D, Ogilvie LA, Hoyle N, Keilholz U, Lange B, Lehrach H on behalf of the OncoTrack Consortium. Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack. **Biotechnology Journal**. 2014;9(9):1104-14.
- Rodon L, Gonzalez-Junca A, Inda MD, Sala-Hojman A, Martínez-Saez E, **Seoane J**. Active CREB1 promotes a malignant TGF- β 2 autocrine loop in glioblastoma. **Cancer Discovery**. 2014;4(10):1230-41.
- Annibaldi D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, Redondo-Campos S, Folch G, Gonzalez-Juncà A, Sodrì NM, Masso-Vallés D, Beaulieu ME, Swigart LB, Mc Gee MM, Somma MP, Nasi S, **Seoane J**, Evan GI, Soucek L. Myc inhibition is effective against glioma and reveals a role for Myc in mitosis. **Nature Communications**. 2014;5:4632.
- De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CK, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, **Seoane J**, Reis-Filho JS. Capturing Intra-Tumor Genetic Heterogeneity by De Novo Mutation Profiling of Circulating Cell-Free Tumor DNA: A Proof-of-Principle. **Annals of Oncology**. 2014;25(9):1729-35.

- Martino-Echarri E, Fernández-Rodríguez R, Bech-Serra JJ, Plaza-Calonge MC, Vidal N, Casal C, Colomé N, **Seoane J**, Canals F, Rodríguez-Manzaneque JC. Relevance of IGFBP2 proteolysis in glioma and contribution of the extracellular protease ADAMTS1. **Oncotarget**. 2014;5(12):4295-304.
- Seoane J**. Gremlins Sabotage the Mechanisms of Cancer Stem Cell Differentiation. **Cancer Cell**. 2014;25(6):716-7.
- Seoane J**, De Mattos-Arruda L. Brain metastasis: new opportunities to tackle therapeutic resistance. Review Article, **Molecular Oncology**. 2014;8(6):1120-31.
- Seoane J**, De Mattos-Arruda L. The challenge of intratumour heterogeneity in precision medicine. **Journal of Internal Medicine** 2014;276(1):41-51.
- Inda MD, Bonavia R, **Seoane J**. Glioblastoma multiforme: a look inside its heterogeneous nature. **Cancers** (Basel). 2014;6(1):226-39.
- Cortés J, Calvo E, Vivancos A, Perez-Garcia J, Recio JA, **Seoane J**. New approach to cancer therapy based on a molecularly defined cancer classification. **CA: A Cancer Journal for Clinicians**. 2014;64(1):70-4.
- De Mattos-Arruda L, Bidard FC, Won HH, Cortes J, Ng CK, Peg V, Nuciforo P, Jungbluth AA, Weigelt B, Berger MF, **Seoane J***, Reis-Filho JS*. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing. **Molecular Oncology**. 2014;8(1):150-8 (*co-corresponding authors).
- Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratu G, Parra JL, De Mattos-Arruda L, Grueso J, Hernandez-Losa J, Arribas J, Prudkin L, Nuciforo P, Scaltriti M, **Seoane J***, Baselga J*. Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation. **Cancer Discovery**. 2013;3(11):1238-44 (*co-corresponding authors).
- De Mattos-Arruda L, Cortes J, Santarpia L, Vivancos A, Tabernero J, Reis-Filho JS, **Seoane J**. Circulating Tumor Cells and Cell-Free DNA as Tools for Managing Breast Cancer. **Nature Reviews. Clinical Oncology**. 2013;10(7):377-89.
- De Mattos-Arruda L, Tabernero J, **Seoane J**, Cortes J. Circulating tumour cells in early breast cancer. **Lancet Oncology**. 2012;13(9):e370.
- Ros-Blanco L, Anido J, Bosser R, Este J, Clotet B, Kosoy A, Ruiz-Avila L, Teixido J, **Seoane J***, Borrell JI*. NonCyclam Tetraamines inhibit CXC Chemokine Receptor Type 4 and target Glioma-Initiating Cells. **Journal of Medicinal Chemistry**. 2012;55(17):7560-70 (*co-corresponding author).
- Eichhorn PJ, Rodon L, González-Juncà A, Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V., Prat A., Cuartas I, Jimenez J, García-Dorado D, Sahuquillo J, Bernards R, Baselga J, **Seoane J**. USP15 stabilizes TGF- β receptor I and promotes oncogenesis through the activation of TGF- β signaling in glioblastoma. **Nature Medicine**. 2012;18(3):429-35. [see News and Views: Aggarwal K and Massagué J. Ubiquitin removal in the TGF- β pathway. *Nature Cell Biology*. 2012;14(7):656-7.
- Anido J, Sáez-Borderías A, González-Juncà A, Rodón L, Folch G, Carmona MA, Prieto-Sánchez RM, Barba I, Martínez-Sáez E, Prudkin L, Cuartas I, Raventós C, Martínez-Ricarte F, Poca MA, García-Dorado D, Lahn M, Yingling J, Rodón J, Sahuquillo J, Baselga J, **Seoane J**. TGF- β receptor inhibitors target the CD44high/Id1high glioma-initiating cell population in human glioblastoma. **Cancer Cell**. 2010;18(6):655-68.
- Seoane J**. NO Signals from the Cancer Stem Cell Niche. **Cell Stem Cell**. 2010;6(2):97-8.
- Seoane J**. TGF- β and cancer initiating cells. **Cell Cycle**. 2009;8(23):3787-8.
- Santamaria-Martínez A, Barquiner J, Barbosa-Desongles A, Hurtado A, Pinós T, **Seoane J**, Poupon MF, Morote J, Reventós J, Munell F. Identification of multipotent mesenchymal stromal cells in the reactive stroma of

- a prostate cancer xenograft by side population analysis. **Experimental Cell Research**. 2009; 315(17):3004-13.
- Peñuelas S, Anido J, Prieto-Sánchez RM, Folch G, Barba I, Cuartas I, García-Dorado D, Poca MA, Sahuquillo J, Baselga J, **Seoane J**. TGF- β increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. **Cancer Cell**. 2009;15(4):315-27.
- Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, **Seoane J**, Bernards R, Baselga J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. **Cancer Research**. 2008;68(22):9221-30.
- Seoane J**. The TGF- β pathway as a therapeutic target in cancer. **Clinical and Translational Oncology**. 2008;10(1):14-19.
- Baselga J, Rothenberg ML, Tabernero J, **Seoane J**, Daly T, Cleverly A, Berry B, Rhoades SK, Ray CA, Fill J, Farrington DL, Anne L, Yingling JM, Lahn M, Arteaga C, Carducci M. TGF- β signaling related markers in cancer patients with bone metastasis. **Biomarkers**. 2008;13(2):217-36.
- Seoane J**. TGF- β signaling in homeostasis and cancer. In: Jakowlew SB (ed.) *Cancer Drug Discovery and Development: Transforming Growth Factor-Beta in Cancer Therapy, Vol. 1: Basic and Clinical Biology*. 1st ed. Totowa, NJ: **Humana Press**; 2008. pp 23-35.
- Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, **Seoane J**. High TGF- β -Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. **Cancer Cell**. 2007;11,147-160.
- Gomis RR, Alarcón C, He W, Wang Q, **Seoane J**, Lash A and Massagué J. A FoxO-Smad synexpression group in human keratinocytes. **PNAS**. 2006;103(34):12747-52.
- Seoane J**. Escaping from the TGF- β anti-proliferative control. **Carcinogenesis**. 2006;27(11):2148-56.
- Massagué J, **Seoane J**, Wotton D. Smad Transcription Factors. **Genes Development**. 2005;19,2783-2810.
- Seoane J**, Le H-V, Shen L, Anderson SA, Massagué J. Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation. **Cell**. 2004;117,211-223 (Cover) [see Preview: Arden KC. FoxO: Linking new signaling pathways. *Molecular Cell*. 2004;14(4):416-8].
- Seoane J**. p21(WAF1/CIP1) at the Switch Between the Anti-Oncogenic and Oncogenic Faces of TGF- β . **Cancer Biology & Therapy**. 2004;3(2):226-7.
- Calonge J, **Seoane J**, Massagué J. Opposite Smad and chicken ovalbumin upstream promoter transcription factor inputs in the regulation of the collagen VII gene promoter by transforming growth factor- β . **Journal of Biological Chemistry**. 2004;279(22):23759-65.
- Seoane J**, Le H-V, Massagué J. Myc suppression of p21(Cip1) Cdk inhibitor determines the outcome of the p53 response to DNA damage. **Nature**. 2002;419(6908):729-34 [see Preview: Vousden KH. Switching from life to death: the Miz-1 link between Myc and p53. *Cancer Cell*. 2002;2(5):351-2].
- Wu J-W, Hu M, Chai J, **Seoane J**, Huse M, Li C, Kyin S, Fairman R, Muir TW, Massagué J, Shi Y. Crystal structure of a phosphorylated Smad2: Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF- β signaling. **Molecular Cell**. 2001;8(6):1277-89.
- Seoane J**, Pouppnot C, Staller P, Schader M, Eilers M, Massagué J. TGF- β influences Myc, Miz-1 and Smad to control the CDK inhibitor p15Ink4b. **Nature Cell Biology**. 2001;3(4):400-8.

- Staller P, Peukert K, Kiermaier A, **Seoane J**, Lukas J, Karsunky H, Moroy T, Bartek J, Massagué J, Hanel F, Eilers M. Repression of p15Ink4b expression by Myc through association with Miz-1. **Nature Cell Biology**. 2001;3,392-399.
- Hata A, **Seoane J**, Lagna G, Montalvo E, Hemmati-Brivanlou A, Massagué J. OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways. **Cell**. 2000;100(2):229-40.
- De la Iglesia N, Mukhtar M, **Seoane J**, Guinovart JJ, Agius L. The role of the regulatory protein of glucokinase in the glucose sensory mechanism of the hepatocyte. **Journal of Biological Chemistry**. 2000;275(14):10597-603.
- Warner BJ, Blain SW, **Seoane J**, Massagué J. Myc downregulation by transforming growth factor beta required for activation of the p15(Ink4b) G(1) arrest pathway. **Molecular and Cellular Biology**. 1999;19(9):5913-22.
- Seoane J**, Barberà A, Telemaque-Potts S, Newgard SB, Guinovart JJ. Glucokinase overexpression restores glucose utilization and storage in cultured hepatocytes from male Zucker diabetic fatty rats. **Journal of Biological Chemistry**. 1999;274(45):31833-8.
- Seoane J**, Trinh K, O'Doherty RM, Gómez-Foix AM, Lange AJ, Newgard CB, Guinovart JJ. Metabolic impact of adenovirus-mediated overexpression of the glucose 6-phosphatase catalytic subunit in hepatocytes. **Journal of Biological Chemistry**. 1997;272(43):26972-7.
- Guinovart JJ, Gómez-Foix AM, **Seoane J**, Fernández-Novell JM, Bellido D, Vilaró S. Bridging the gap between glucose phosphorylation and glycogen synthesis in the liver. **Biochemical Society Transactions**. 1997;25(1):157-60.
- Seoane J**, Gómez-Foix AM, O'Doherty RM, Gómez-Ara C, Newgard CB, Guinovart JJ. Glucose 6-phosphate produced by glucokinase, but not hexokinase I, promotes the activation of hepatic glycogen synthase. **Journal of Biological Chemistry**. 1996;271(39):23756-60.
- O'Doherty RM, Lehman DL, **Seoane J**, Gómez-Foix AM, Guinovart JJ, Newgard CB. Differential metabolic effects of adenovirus-mediated glucokinase and hexokinase I overexpression in rat primary hepatocytes. **Journal of Biological Chemistry**. 1996;271(34):20524-30.

Grants

Grantor: ISCIII-PFIS

Title: Estudio del microambiente inmunosupresor del tumor cerebral

Project Reference: PI19/00318

Role in the Project: Principal Investigator | 2020-2022

Grantor: Generalitat de Catalunya – Departament de Salut

Title: an anti-LIF therapeutic antibody, as a potential treatment for CoVid19

Project Reference: COVID19-PoC

Role in the Project: Principal Investigator | 2020

Grantor: Fundació Catalunya La Pedrera

Title: Programa joves i ciència

Role in the Project: Principal Investigator | 2019 – 2020

Grantor: FERO

Title: Caracterización molecular mediante el estudio del ADN circulante en líquido cefalorraquídeo para la mejora del tratamiento del tumor cerebral pediátrico, meduloblastoma.

Role in the Project: Principal Investigator | 2019-2020

Grantor: Fundación ARECES.

Title: Identification of novel immunotherapeutic targets in lung and melanoma brain metastases
Role in the Project: Principal Investigator | 2019-2022

Grantor: **BBVA**

Title: Impact of the brain tumor microenvironment on the response of brain malignancies to immunotherapies.
Role in the Project: Principal Investigator | 2018

Grantor: Agència de Gestió d'Ajuts Universitaris i de Recerca (**AGAUR**) Servei General de Recerca (SGR).

Title: Ajuts de Suport a la recerca - Grups de Recerca Consolidats

Project Reference: 2017SGR528

Role in the project: Principal Investigator | 2017-2020

Grantor: **ISCIII-PFIS**

Title: "Contrato predoctoral de formación en investigación en salud"

Project Reference: FI17/00345

Role in the Project: Principal investigator | 2018-2021

Grantor: **Fundación Científica de la AECC.**

Title: "Study of the molecular mechanisms involved in primary (glioblastoma) and secondary (metastasis) brain tumors to identify novel therapeutic targets and anti-cancer agents, biomarkers to select treatments and novel non-invasive methods for molecular diagnosis.

Project Reference: GCTRA16015SEDA

Role in the Project: Principal Investigator | 2017-2022

Grantor: **IBEC-La Caixa**

Title: "Understanding and measuring mechanical tumor properties to improve cancer diagnosis, treatment, and survival: Application to liquid biopsies"

Role in the Project: Principal Investigator | 2017-2020

Grantor: Institute of Health Carlos III – FIS (**Ministry of Science and Innovation-MICINN**)

Title: "Identificación de mecanismos de resistencia a tratamiento a través del estudio de la heterogeneidad intratumoral en glioblastoma"

Project Reference: Ref. PI16/01278

Role in the project: Principal Investigator | 2017-2019

Grantor: Institute of Health Carlos III – FIS (**Ministry of Science and Innovation-MICINN**)

Title: CIBER – Área Temática: Characterization and therapeutic use of stem cells and organoids in cancer

Project Reference: Ref. CB16/12/00450

Role in the project: Principal Investigator | 2017-2018

Grantor: **FERO**

Title: "Caracterización molecular de los tumores cerebrales pediátricos mediante el estudio del DNA circulante en sangre y líquido cefalorraquídeo"

Role in the project: Principal investigator | 2015-2018

Grantor: **MINECO-RETOS**

Title: "Desarrollo de un fármaco innovador y personalizado para el tratamiento del cáncer que reactiva el sistema inmune contra el tumor y elimina las células madre tumorales"

Project Reference: RTC-2015-3771-1

Role in the project: Principal Investigator | 2015-2018

Grantor: **European Commission, European Research Council (ERC) Proof of Concept Grant**

Title: "Development of a more effective and safer therapeutic antibody for cancer treatment with a dual mechanism of action to eliminate CSCs and reactivate the tumour's immune system". CSC-IS

Project reference: 665671

Role in the project: Principal Investigator | 2015-2016

Grantor: **MINECO-RETOS**

Title: "MSC-1, un fármaco innovador y personalizado para el tratamiento del cáncer con un doble mecanismo de acción: ataca las células madre tumorales y reactiva el sistema inmune del tumor".

Role in the project: Principal Investigator | 2014-2017

Grantor: Agència de Gestió d'Ajuts Universitaris i de Recerca (**AGAUR**)

Title: Servei General de Recerca (SGR). Grups de Recerca Consolidats

Project Reference: 2014SGR1335

Role in the project: Principal Investigator | 2014-2017

Grantor: Institute of Health Carlos III – FIS (**Ministry of Science and Innovation-MICINN**)

Title: "Heterogeneidad intra-tumoral en glioblastoma. Implicaciones terapéuticas".

Project Reference: PI13/02661

Role in the project: Principal Investigator | 2014-2016

Grantor: The **Dr. Josef Steiner Cancer Research Foundation**

Title: "Molecular mechanisms implicated in glioblastoma and glioma-initiating cells. Identification of therapeutic targets and biomarkers of response to treatments against glioblastoma".

Role in the project: Principal Investigator | 2013-2017

Grantor: Institute of Health Carlos III – FIS (**Ministry of Science and Innovation-MICINN**)

Title: Red Temática de Investigación Cooperativa del Cáncer (RTICC)

Project Reference: RD12/0036/0043

Role in the project: Principal Investigator | 2013-2017

Grantor: **Innovative Medicine Initiative-IMI**

Title: "Study of the CD44 high cancer stem cells".

Role in the project: Principal Investigator | 2013-2016

Grantor: European Research Council (**ERC**) Proof of Concept Grant

Title: "Targeting Cancer Stem Cells (CSC) for the development of more effective treatments to cure cancer patients"

Project reference: 324592

Role in the project: Principal Investigator | 2012-2013

Grantor: **CERCA** (Agency for the Research Centres of Catalonia) – Prova't Grant

Title: "Use of peptide shuttles for the delivery of monoclonal antibodies across the blood-brain barrier in brain tumours"

Role in the project: Principal Investigator | 2012-2014

Grantor: European Commission, Marie Curie International Reintegration Grant

Title: Role of Notch signaling pathway in Glioma Stem Cells

Role in the project: Principal Investigator | 2012-2014

Grantor: Institute of Health Carlos III – FIS (**Ministry of Science and Innovation-MICINN**)

Title: "Estudio de los mecanismos moleculares implicados en la génesis del glioma y estudio de las células madre tumorales"

Project Reference: PI10/01848

Role in the project: Principal Investigator | 2011-2015

Grantor: Agencia de Gestió d'Ajuts Universitaris i de Recerca (**AGAUR**)

Title: Proyecto relacionado con Beca postdoctoral del programa Beatriz de Pinos.

Role in the Project: Principal Investigator | 2010-2012

Grantor: Asociación Española Contra el Cáncer (**AECC**)

Title: "Mecanismos moleculares implicados en la génesis del glioma y estudio de las células madre tumorales. Identificación de nuevas dianas terapéuticas y marcadores para estratificación de pacientes y respuesta a fármacos"

Role in the project: Principal Investigator | 2010-2015

Grantor: Asociación Española Contra el Cáncer (**AECC**)

Title: "Function of the TGF- β , PI3K and JAK-STAT signalling pathways in glioma initiating cells.

Role in the Project: Principal Investigator | 2010-2014

Grantor: Ministry of Science and Innovation (**MICINN**)

Title: "EMBO YIP"

Project Reference: SAF2008-04778-E

Role in the project: Principal Investigator | 2009-2013

Grantor: Ministry of Science and Innovation (**MICINN**)

Title: "An integrated approach to post-transcriptional regulation of gene expression and its role in human disease"

Project Reference: CSD2009-00080

Role in the project: Principal Investigator | 2009-2014

Grantor: Agencia de Gestió d'Ajuts Universitaris i de Recerca (**AGAUR**)

Title: Servei General de Recerca (SGR). Suport a Grups de Recerca de Qualitat.

Project Reference: 2009SGR504

Role in the project: Principal Investigator | 2009-2014

Grantor: European Research Council (**ERC**)

Title: "Molecular mechanisms of glioma genesis and progression"

Project reference: 205819-Glioma

Role in the project: Principal Investigator | 2008-2014

Grantor: Institute of Health Carlos III – FIS (**Ministry of Science and Innovation-MICINN**)

Title: "Papel del TGF- β en la capacidad de auto-regeneración de las células madre de glioma"

Project Reference: PI070648

Role in the project: Principal Investigator | 2008-2011

Grantor: Association for International Cancer Research (**AICR**)

Title: "Role of FoxG1 in glioma"

Role in the project: Principal Investigator | 2006-2009

Grantor: Institute of Health Carlos III – FIS (**Ministry of Science and Innovation-MICINN**)

Title: "Estudio de los mecanismos moleculares implicados en la génesis de glioma y estudio de las células madre tumorales"

Project Reference: PI040766

Role in the project: Principal Investigator | 2005-2008

Grantor: **European Commission, Marie Curie International Reintegration Grant**

Title: "Molecular mechanisms of gliomagenesis"

Project Reference: 017121-Glioma

Role in the project: Principal Investigator | 2005-2007

Participation in Research Contracts

Grantor: **Hoffmann-La Roche, Ltd.**

Title: Deciphering mechanism of early disease relapse in BRAF mutant brain metastatic melanoma.

Principal Investigator: Joan Seoane | 2019-2021

Grantor: **Mosaic Biomedicals**

Title: Assess whether the presence of high levels of LIF in the tumor can predict resistance to CPI

Principal Investigator: Joan Seoane | 2019

Grantor: **Roche Glycart AG**

Title: Preclinical Study of EGFRVIII TCBs in GBM

Principal Investigator: Joan Seoane | 2018-2019

Grantor: **Mosaic Biomedicals**

Title: Identify PD biomarkers and biomarkers to predict response to MSC1 treatment

Principal Investigator: Joan Seoane | 2018-2019

Grantor: **Ridgeline Therapeutics, GmbH**

Title: Test Ridgeline compounds in VHIO's PDX model and molecular characterization of HNSCC tissue samples.

Principal Investigator: Joan Seoane | 2017-2019

Grantor: **Mosaic Biomedicals**

Title: Preclinical evaluation of MOSAIC's MSC-1 antibody

Principal investigator: Joan Seoane | 2016-2017

Grantor: **Mosaic Biomedicals**

Title: Preclinical evaluation of MOSAIC's MSC-1 antibody

Principal investigator: Joan Seoane | 2015-2018

Grantor: **AstraZeneca**

Title: Defining clinically actionable genetic alterations in DNA repair with in vivo response to the PARP inhibitor Olaparib

Principal investigator: Joan Seoane | 2014-2017

Grantor: **Mosaic Biomedicals**

Title: Preclinical evaluation of MOSAIC's MSC-1 antibody

Principal investigator: Joan Seoane | 2014-2017

Grantor: **Eli Lilly**

Title: Analysis of the TGF- β and type C signature in colorectal cancer

Principal investigator: Joan Seoane | Jan 2015-Sept 2015

Grantor: **ISARNA Therapeutics GmbH**

Title: Preclinical Evaluation of Isarna Next Generation Oligos (NGOs)

Principal Investigator: Joan Seoane | 2013 - 2018

Grantor: **Novartis**

Therapeutic inhibition of the oncogenic Wnt/beta-catenin pathway

Equipo investigador: Joan Seoane, Ana Vivancos, Héctor García Palmer | 2013 –2015

Grantor: **Eli Lilly**

Title: Effect of the T β RI/BMPRI dual inhibitor on glioblastoma and glioma-initiating cells

Principal Investigator: Joan Seoane | 2011- 2017

Grantor: **Janus**

Title: Effect of CXCR4 inhibitors on glioma initiating cells

Principal Investigator: Joan Seoane | 2010

Grantor: **Novartis**

Title: Effect PI3K inhibitors on glioma and glioma initialing cells

Principal Investigator: Joan Seoane |2009- 2012

Grantor: **Eli Lilly**

Title: Preclinical studies with the TGF- β receptor I inhibitor LY02109761

Principal Investigator: Joan Seoane |2006 - 2010

Grantor: **Merck Sharp and Dohme**

Title: Role of TGF- β in neuroprogenitor self-renewal

Principal Investigator: Joan Seoane |2005 - 2008

Patents

Title: **Methods for Improving Response to Anti-LIF Antibody Treatment in Individuals with Cancer**

Application n./Patent N: US non-provisional and PCT filing due 6/18/2019

Licensed to Mosaic Biomedicals, S.L.U et al.

Register Date: June 18th, 2018

Title: **Combination of LIF Inhibitors and Platinum-based Antineoplastic Agents for Use in Treating Cancer**

Application n./Patent N: US non-provisional and PCT filing due 6/18/2019

Licensed to Mosaic Biomedicals, S.L.U et al.

Register Date: June 18th, 2018

Title: **Methods of Quantifying LIF and Uses Thereof**

Application n./Patent N: US non-provisional and PCT filing due 6/18/2019

Licensed to Mosaic Biomedicals, S.L.U et al.

Register Date: June 18th, 2018

Title: **Antibodies against LIF and dosage forms thereof.**

Application n./Patent N: US non-provisional and PCT filing due 5/14/2019

Licensed to Mosaic Biomedicals, S.L.U et al.

Register Date: May 14th, 2018

Title: **Combination Of Lif Inhibitors And Pd-1 Axis Inhibitors For Use In Treating Cancer.**

Application N./Patent N: 18382248.5-1111

Licensed to Mosaic Biomedicals, S.L.U et al.

Register Date: April 12th, 2018

Title: **Antibodies Against Lif And Uses Thereof**

Application N./Patent N.: EP16382617.5

Licensed to Mosaic Biomedicals, S.L.

Register Date: December 19th, 2016.

Title: **Agents For The Treatment Of Diseases Associated With Undesired Cell Proliferation.**

Application N./ Patent N.: P12417EP00

Licensed to Mosaic Biomedicals, S.L.

Register Date: November 27th, 2015.

Title: **Antibody Recognizing Human Leukaemia Inhibitory Factor (Lif) And Use Of Anti-Lif Antibodies In The Treatment Of Diseases Associated With Unwanted Cell Proliferation.**

Application N./ Patent N.: EPA1038049.6

Licensed to Mosaic Biomedicals, S.L.

Register Date: April 5th, 2010.

Title: **Therapeutic Agents For The Treatment Of Diseases Associated With Undesired Cell Proliferation.**

Application N./ Patent N.: ESA200900928

Other activities

- **Local Chair** organizer of the 22nd Biennial Congress of the European Association for Cancer Research (EACR22), Barcelona, 2012.
- **Faculty member** of the "Cancer Research" Faculty Group, European Society for Medical Oncology (ESMO), 2015-present.
- **Reviewer** of the following journals: Nature, Cell, Nature Cell Biology, Cancer Cell, Cell Stem Cell, EMBO Journal, Journal of Chemistry, Carcinogenesis, Nucleic Acids Research, Journal of Cell Biology, Oncogene, Cancer Research, Clinical Cancer Research, Neuro-Oncology.
- **Member of the Scientific Committee**, Fundación Seve Ballesteros, April 2013.
- **Founder and Chairman** of Mosaic Biomedicals, May 2012. The company has received the following awards:
 - **BioExit 2017** (CataloniaBio) | March 2017
 - **Mejor Proyecto Emprendedor en Biotecnología** (ASEBIO, Genoma España, SEBiot, SEBBM) | 2012
 - **Mejor Proyecto en Biotecnología de España** (FECyT) | 2012
 - **Emprendedor XXI** (La Caixa) | June 2012
- **Member of the Scientific Advisory Board** for the Cancer Research UK Manchester Institute
- **Chairman** of the EACR Conference Series meetings since 2014
- **Member of the ESMO Translational Research and Personalized Medicine Working Group**, January 2016.
- **Co-Chairperson organizer** of the Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic, organized by the American Association for Cancer Research (AACR). February 11-14, 2016. New Orleans, LA.
- **Member of the Editorial Board** of Molecular Oncology, November 2016.
- **Chair & Organizer** of the EACR Conference: 'Defence is the Best Attack: Immuno-Oncology Breakthroughs', Barcelona, Spain, October 9-11th, 2017, March 11-13th, 2019 and February 16th-17th, 2021.
- **Member of the Scientific Steering Committee** for ESMO Madrid 2017 Conference.
- **Interviewed** for [ESMO Perspectives](#) (the ESMO Digital Magazine): Patient-Derived Tumour Models: The Clinic Mimics. Issue 3, 2017.
- **Member of the Scientific Steering Committee** for ESMO Munich 2018 Congress.
- **Chair & Organizer** of the EACR Conference: LIF As We Know It: From Basic Science to Clinical Trials. Barcelona, Spain, May 28th-29th, 2018.
- **Member of the Executive and Scientific Committee** organizer of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, June 30th -July 3rd, 2018.
- **Chair & Organizer** of the EACR Conference: 'Defence is the Best Attack: Immuno-Oncology Breakthroughs', Barcelona, Spain, March 11-13th, 2019.

- **Member** of the Bosarge Family Foundation-Waun Ki Hong Scholar Award for Regenerative Cancer Medicine **Scientific Review Committee** (from AACR) since 2019.
- **Member of the Scientific Committee** organizer of ESMO 2019 Congress in partnership with the EACR, Barcelona, Spain, September 26th – 30th, 2019.
- **Member of the Executive and Scientific Committee** organizer of EACR2020 Congress, Torino, Italy, June 17th-20th, 2020.
- **Member of the Scientific Committee** organizer of ESMO2020 Congress, Madrid, Spain, September 18th-22nd, 2020.
- **Faculty member at the Grand Challenge International Consultation Workshop** organized by Fundación de la AECC & Cancer Research UK, Madrid, Spain, 8th July 2019.
- **Interviewed for ESMO Society News:** Implications and future of targeted methylation analysis of cfDNA and its role in the early detection of tumours. A discussion with Professor Joan Seoane. 2020 April 3rd.
- **Member of the Scientific Committee** organizer of EACR2022 Congress, Sevilla, Spain, June 20th-23rd 2022.
- **Chair & Organizer** of the EACR Conference: 'Defence is the Best Attack: Immuno-Oncology Breakthroughs'. Virtual event Worldwide, February 16-17th, 2021.
- Chair & Speaker at the **AACR Annual Meeting 2021**. Virtual event Worldwide, April 9-14th and May 17-21st, 2021

Doctoral Theses supervised

"Role of HLA-G in shaping Natural Killer cell biology in cancer", Universitat de Barcelona, Spain.
 Doctoral Student: Ester Arroba - Dissertation date: 10 February 2021.

"The Oncogenic of LIF function in glioblastoma", Universitat de Barcelona, Spain.
 Doctoral Student: Ada Sala Hojman - Dissertation date: 15 July 2016

"Genomic characterization of brain malignancies through liquid biopsies: The cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma"
 Universitat Autònoma de Barcelona, Spain
 Doctoral Student: Leticia de Mattos Arruda - Dissertation date: 29 June 2016

"FOXG1 confers resistance to PI3K inhibitors through repressing FOXO activity in glioma"
 Universitat de Barcelona, Spain
 Doctoral student: Gerard Folch - Dissertation date: 26 January 2016

"Study of the molecular mechanisms implicated in the TGF-Beta oncogenic effect in glioma."
 Universitat de Barcelona, Spain
 Doctoral student: Alba González Juncà - Dissertation date: 15 November 2013

"Hyperactivation of the TGF-beta signaling pathway in glioblastoma: mechanisms and consequences."
 Universitat de Barcelona, Spain
 Doctoral student: Laura Rodón Ahnert - Dissertation date: 28 November 2012

"Study of the TGFβ/PDGF-B axis in lung adenocarcinoma."
 Universitat de Barcelona, Spain
 Doctoral student: Francisco Miguel Torres Grande - Dissertation date: 8 June 2011

Teaching experience in courses and seminars for university

2021

Master Bioquímica i Biologia Molecular (UAB)
Universitat Autònoma de Barcelona (UAB)
Barcelona, Spain | 15th February 2021

Master in Translational Biomedical Research: Neoplastic Diseases
Oncology Master (UAB) Vall d'Hebron University Hospital
Fundació Institut de Recerca de l'Hospital Universitari Vall d'Hebrón (VHIR).
Barcelona, Spain | 7th January 2021

2020

Perspectivas futuras en el diagnóstico molecular de los tumores primarios y metástasis del SNC: biopsia líquida

XV Curso de Neuro-Oncología Médica – Grupo Español de Investigación en Neuro-Oncología (GEINO)
Vall d'Hebron University Hospital
Webinar | 24th -25th November 2020

From a clinical problem to a clinical trial.

Programa de Formació en Recerca per a Residents
Master In Translational Biomedical Research 2020-2021.
Vall d'Hebron Institut de Recerca (VHIR) + Universitat Autònoma de Barcelona (UAB)
Webinar | 27th October 2020

LIF in cancer. From bench to clinical trial

Master UAB - Dept. Bioquímica i Biologia Molecular - Institut de Neurociències
Facultat de Medicina (UAB)
Barcelona, Spain | 19th February 2020

2019

Máster Oficial en Farmacología – Farmacológica
Universitat Autònoma de Barcelona (UAB).
Barcelona, Spain | 6th November 2019

LIF. Potential therapeutic approach in PDAC

Course: "Top Highlights in Pancreatic adenocarcinoma (PDAC)
Vall d'Hebron Hospital Universitari
Barcelona, Spain | 4th October 2019

Bases Moleculares de Transducción de Señales i del Càncer
Master UAB - Dept. Bioquímica i Biologia Molecular - Institut de Neurociències
Facultat de Medicina (UAB)
Barcelona, Spain | 22nd February 2019

From discovery to clinical trials. Designing new anti-cancer drugs
Course: Oncología Médica (UAB) Vall d'Hebron University Hospital
Vall d'Hebron Institut d'Oncologia (VHIO)
Barcelona, Spain | 24th January 2019

· Master en Oncología Molecular

CNIO – Centro de Estudios Biosanitarios (CEB)
Madrid, Spain | Online Edition (2018-2019)

2018

- Master in Translational Biomedical Research: Neoplastic Diseases
Oncology Master (UAB) Vall d'Hebron University Hospital
Fundació Institut de Recerca de l'Hospital Universitari Vall d'Hebrón (VHIR).
Barcelona, Spain | *17th December 2018*
- Molecular mechanisms involved in the genesis and progression of brain cancer
Master Biomedicine
Universitat de Barcelona (UB)
Barcelona, Spain | *30th November 2018*
- Heterogeneidad intratumoral y su evolución en la progresión tumoral.
Implicaciones biológicas y clínicas.
Programa interdisciplinar de Patología Molecular Diagnóstica
Hospital Universitari Vall d'Hebron (HUVH)
Barcelona, Spain | *16th November 2018*
- Máster Oficial en Farmacología – Farmacológica
Universitat Autònoma de Barcelona (UAB).
Barcelona, Spain | *9th November 2018*
- “The role of tumour microenvironment in Immunotherapy”.
Medical Education Program on Immunotherapy
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain | *17th May 2018*
- “Dealing with intra-tumor heterogeneity in brain cancer”
V Ciclo Seminarios Biomedicina
Instituto de Investigaciones Biomédicas Alberto Sols (IIBM) CSIC-UAM
Madrid, Spain | *21st february 2018*
- Tumor heterogeneity - Módulo Señalización y Cáncer
Máster de Bioquímica y Biomedicina
Universitat Autònoma de Barcelona (UAB)
Barcelona, Spain | *9th february 2018*

2017

- Master en Oncología Molecular
CNIO – Centro de Estudios Biosanitarios (CEB)
Madrid, Spain | Online Edition (2017-2018)
- Máster Oficial en Farmacología – Farmacológica
Universitat Autònoma de Barcelona (UAB)
Barcelona, Spain | *10th November 2017*
- Master in Translational Biomedical Research: Neoplastic Diseases
Oncology Master (UAB) Vall d'Hebron University Hospital
Fundació Institut de Recerca de l'Hospital Universitari Vall d'Hebrón (VHIR).
Barcelona, Spain | *9th November 2017*

- Intratumor heterogeneity in brain cancer
Università degli Studi di Torino
Seminar. Candiolo Cancer Institute IRCCS
Candiolo, Torino, Italy | 19th January 2017
- Master in Translational Biomedical Research: Neoplastic Diseases
Oncology Master (UAB) Vall d'Hebron University Hospital
Fundació Institut de Recerca de l'Hospital Universitari Vall d'Hebron (VHIR)
Barcelona, Spain | 10th January 2017

2016

- Bases biològiques del càncer (II) – Bases moleculars del procés de disseminació.
Licenciatura Mèdica: Assignatura Oncologia Mèdica
Universitat Autònoma de Barcelona (UAB)
Barcelona, Spain | 1st December 2016
- Máster Oficial en Farmacología – Farmacológica
Universitat Autònoma de Barcelona (UAB)
Barcelona, Spain | 11th November 2016
- *Máster* en Oncología Molecular (on-line): TGF-Beta y gliomas
Centro Nacional de Investigaciones Oncológicas (CNIO)
On line, Spain | 1st October 2016
- Master in Translational Biomedical Research: Neoplastic Diseases
Oncology Master (UAB) Vall d'Hebron University Hospital
Fundació Institut de Recerca de l'Hospital Universitari Vall d'Hebrón (VHIR)
Barcelona, Spain | 14th January 2016

2015

- *Máster* Oficial en Farmacología – Farmacológica
Universitat Autònoma de Barcelona (UAB)
Barcelona, Spain | 11th November 2015
- *Impacte* de la heterogeneïtat intratumoral sobre la progressió del càncer
Seminar
Universitat Autònoma de Barcelona (UAB).
Barcelona, Spain | 4th November 2015
- Bases *biológicas* del cancer (II) – Bases moleculares del proceso de diseminación
Licenciatura Mèdica: Assignatura Oncologia Mèdica
Universitat Autònoma de Barcelona (UAB)
Barcelona, Spain | 2nd November 2015
- *Bases Moleculares del Cáncer*
Master en Oncología Molecular (on-site and online Edition)
CNIO - Centro de Estudios Biosanitarios (CEB)
Madrid, Spain | 18th September 2015
- *Curso* de Formación de Ensayos Clínicos en Oncología
Seminar
Fundació Institut de Recerca de l'Hospital Univ. Vall d'Hebron (VHIR)
Barcelona, Spain | 3rd July 2015

- *Principios de Oncología Molecular I*
Licenciatura Médica
Universitat Autònoma de Barcelona (UAB)
Barcelona, Spain | 2015

2014

- Master in Translational Biomedical Research: Neoplastic Diseases
Oncology Master (UAB) Vall d'Hebron University Hospital
Fundacio Institut de Recerca de l'Hospital Univ. Vall d'Hebron (VHIR)
Barcelona, Spain | 16th December 2014
- *Máster en Farmacología*
Máster
Universitat Autònoma de Barcelona (UAB)
Barcelona, Spain | 6th November 2014
- *Principios de Oncología Molecular I*
Licenciatura Médica
Universitat Autònoma de Barcelona (UAB)
Barcelona, Spain | 22nd October 2014
- *Bases Moleculares del Cáncer*
Master en Oncología Molecular (on-site and online Edition)
CNIO - Centro de Estudios Biosanitarios (CEB)
Madrid, Spain | 19th September 2014
- *Curso Breast Cancer Management. "Angiogénesis y cáncer"*
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain | June 2014

2013

- *Principios de Oncología Molecular I*
Licenciatura Médica
Universitat Autònoma de Barcelona (UAB)
Barcelona, Spain | 4th October 2013
- *Curso de Formación de Ensayos Clínicos en Oncología*
Workshop
Vall d'Hebron University Hospital
Barcelona, Spain | July 2013
- *Bases Moleculares del Cáncer*
Master en Oncología Molecular (on-site and online Edition)
CNIO – Centro de Estudios Biosanitarios (CEB)
Madrid, Spain | 5th July 2013

2012

- *Principios de Oncología Molecular I*
Licenciatura Médica
Universitat Autònoma de Barcelona (UAB)
Barcelona, Spain | 8th October 2012
- *Curso "Anticuerpos Monoclonales en Cáncer de Mama. Optimizando estudios clínicos y sus*

resultados”
Workshop
Hospital Valle de Hebrón Barcelona
Barcelona, Spain | *March 2012*

- *Bases Moleculares del Cáncer*
Master en Oncología Molecular
CNIO – Centro de Estudios Biosanitarios (CEB)
Madrid, Spain | *4th May 2012*

2011

- *Bases Moleculares del Cáncer*
Master en Oncología Molecular
CNIO – Centro de Estudios Biosanitarios (CEB)
Madrid, Spain | *11th March 2011*
- *Curso “Anticuerpos Monoclonales en Cáncer de Mama. Optimizando estudios clínicos y sus resultados”*
Workshop
Hospital Valle de Hebrón Barcelona
Barcelona, Spain | *12th May 2011*

2010

- *Bases Moleculares del Cáncer*
Master en Oncología Molecular
CNIO – Centro de Estudios Biosanitarios (CEB)
Madrid, Spain | *15th January 2010*

2008

- *Bases Moleculares del Cáncer*
Master en Oncología Molecular
CNIO – Centro de Estudios Biosanitarios (CEB)
Madrid, Spain | *14th November 2008*

2007

- *Bases Moleculares del Cáncer*
Master en Oncología Molecular
CNIO – Centro de Estudios Biosanitarios (CEB)
Madrid, Spain | *6th July 2007*

2004

- *Paper del TGF-B en oncogénesis*
Seminar
Departament Bioquímica Campus Bellvitge Universitat de Barcelona (UB).
Barcelona, Spain | *2004*
- *Curso animales modificados genéticamente: presente y futuro en la investigación biomédica*
Curso
Universidad de Santiago de Compostela.
Santiago de Compostela, Spain | *2004*

- *Máster en Investigación Biomédica Traslacional: Oncology Diseases*
Máster
Fundacio Institut de Recerca de l'Hospital Univ. Vall d'Hebron (VHIR)
Barcelona, Spain | 2004
- *Principios de Oncología Molecular I*
Licenciatura Médica
Universitat Autònoma de Barcelona (UAB)
Barcelona, Spain | 2004

Invited Lectures and Oral Communications

2021

LIF as a therapeutic target in cancer
Partners of Choice Scientific Exchange
AstraZéneca
Virtual Event | 22-23rd April 2021

Immunomodulation in cancer and embryogenesis
AACR Annual Meeting 2021
Virtual Event | 9-14th April, 2021

Cancer meets virus. LIF as a regulator of the innate immune response to antigens
Vall d'Hebron Institut de Recerca (VHIR)
Webinar | 24th March 2021

TGF-beta, LIF and extended families
ESMO TAT Virtual Congress 2021
European Society for Medical Oncology (ESMO)
Virtual Conference | 2nd March 2021

Tumor Immune Microenvironment in Brain Cancer
EACR Defence is the Best Attack: Immuno-Oncology Breakthroughs
European Association for Cancer Research (EACR)
Virtual Conference | 16-17th February 2021

Novel therapeutic targets and monitoring tools in brain malignancies
V Jornadas Anuales CIBERONC
CIBERONC – Instituto de Salud Carlos III
Virtual Meeting | 11th february 2021

Circulating tumour DNA from the cerebrospinal fluid allows the characterization and monitoring of medulloblastoma
VI Simposio “Biopsia Líquida: El camino a la oncología de precisión”
Instituto de Investigaciones Sanitarias de Santiago de Compostela.
Virtual Meeting | 26th January 2021

2020

Investigación e innovación en cáncer para mejorar la supervivencia
Semana de la Ciencia - Conferencia
Fundación Científica de la AECC
Webinar | 16th November 2020

Liquid biopsy in brain cancer. Getting beyond blood.

Key Note Presentation
ISLB Congress in Liquid Biopsy 2020
International Society of Liquid Biopsy (ISLB)
Webinar | 30th October 2020

La biopsia líquida. Nuevo método diagnóstico.

Jornada de Cancer de Mama
AECC
Webinar | 19th October 2020

cfDNA in CNS tumors

ESMO Virtual Congress 2020
Educational Weekend
Webinar | 17th October 2020

The role of TGF- β inhibition in colorectal cancer: new perspectives

Tour d'Europe in Colorectal Cancer
Vall d'Hebron University Hospital
Virtual Meeting | 6-7th October 2020

Novel therapeutic targets and monitoring tools in brain malignancies

Seminar - Candiolo Cancer Institute
University of Torino, Italy
Webinar | 12th June 2020

Liquid biopsies and novel therapeutic targets in brain primary tumours and metastasis.

Virtual Meet the Expert, EACR
Webinar | 29th May 2020

Novel targets and biomarkers in primary and metastatic brain cancer

Seminar
Cancer Research UK (CRUK), Manchester UK
Webinar | 27th March 2020

Liquid Biopsy

Second Zurich Brain Metastases Symposium
University Hospital Zurich
Zurich, Switzerland | 16th January 2020

2019

Immunomodulation in embryogenesis and cancer

ESMO Immuno-Oncology Congress 2019
Geneva, Switzerland | 12th December 2019

Oncology meets embryology. LIF in cancer, from the lab to the clinical trial

Barcelona BioMed Conference: Immunotherapy beyond cancer. A cure for age-related diseases
Barcelona, Spain | 18th November 2019

El tumor cerebral: un gran reto para la investigación

Jornada divulgativa sobre el tumor cerebral
AECC
Barcelona, Spain | 12th November 2019

Development of a novel agent (MSC-1) to reactivate an immune call by LIF blockade

Immuno-Oncology Profiling Congress 2019
Palau de Congressos de Catalunya
Barcelona, Spain | 30th October 2019

LIF in cancer

AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
Hynes Convention Center
Boston, Ma, USA | 29th October 2019

Liquid Biopsy in Brain Tumors

CIBER-BBN 2019 Annual Conference
Hotel SB Ciutat de Tarragona
Tarragona, Spain | 21st October 2019

"Embryology meets Oncology. Role of LIF in glioblastoma"

XVIII Congreso de la Sociedad Española de Biología Celular
Edificio Institutos Universitarios
Badajoz, Spain | 16th October 2019

Basic science

Poster Discussant
ESMO Congress 2019
Fira Gran Via Barcelona
Barcelona, Spain | 29th September 2019

Innate immune system and anti-mitotic agents: Two fields getting together

Special Session 1 – Chair and Speaker
ESMO Congress 2019
Fira Gran Via Barcelona
Barcelona, Spain | 27th September 2019

Cell-free tumor DNA

14th EANO Meeting
Centre de Congrès, CITÉ
Lyon, France | 20th September 2019

The immunosuppressive role of LIF in cancer

Canadian Cancer Immunotherapy Consortium meeting,
Mount Sinai Hospital
Toronto, Canada | 19th September 2019

The oncogenic role of the cytokine LIF. Parallelisms between Oncology and Embryology

Seminar
The Donnelly Centre, University of Toronto
Toronto, Canada | 18th September 2019

TGF β Signaling and Immuno-oncology

I ASEICA-ASPIC INTERNATIONAL MEETING: Current Trends In Immunotherapy Research And Treatment
Centro de Investigación del Cáncer
Salamanca, Spain | 13th September 2019

Sortides professionals a la Carrera Acadèmica I Investigadora

II Jornada d'Orientació Professional VHIR
Vall d'Hebron Institut de Recerca
Barcelona, Spain | 11th June 2019

Liquid biopsies in brain cancer
Brain Tumor Meeting 2019
Max Delbrück Communications Center
Berlin, Germany | 24th May 2019

Liquid biopsies from brain tumours
EACR-ESMO Liquid Biopsies 2019
Centro Congressi Giovanni XXIII
Bergamo, Italy | 15th May 2019

Biology of Leukemia Inhibitory Factor (LIF) and role in cancer
Seminar
Celgene Corporation
Seattle, USA | 25th March 2019

Embryology meets Oncology. The role of LIF in cancer
EACR Conference: Defence is the Best Attack 2nd Edition
La Pedrera
Barcelona, Spain | 12th March 2019

Immunomodulation in embryogenesis and cancer
EACR Conference: Tracking Cancer 2019
CosmoCaixa Science Museum
Barcelona, Spain | 6th February 2019

2018

"Embryology meets oncology. The immunomodulatory role of LIF in cancer"
Simposio Científico
"VIII Centenario Universidad de Salamanca: Nuevos retos en investigación oncológica"
Salamanca, Spain | 27th November 2018

"Situació actual de la recerca oncològica"
XXXII Jornada d'avenços en la prevenció, el diagnòstic i el tractament del càncer (AECC)
Facultat de Medicina de la UB
Barcelona, Spain | 24th November 2018

"Understanding the role of TGFbeta signalling in cancer"
NCRI Cancer Conference 2018
Scottish Event Campus
Glasgow, UK | 6th November 2018

"La lluita contra el càncer. Com vèncer un enemic heterogeni, canviant i parcialment desconegut"
Aula de la Universitat a l'Abast
La Garriga, Barcelona, Spain | 30th October 2018

BCN Inspiracy Talks Interview
CosmoCaixa
Barcelona, Spain | 27th October 2018

"CNS tumours" - Proffered Paper session
ESMO 2018 Congress
Discussant
Messe Munich
Munich, Deutschland | 19th October 2018

"LIF and the innate immune response. Linking embryology and cancer"

1st Oncobell International Symposium
Hospital Duran i Reinald
Barcelona, Spain | 21st September 2018

"Embryology meets oncology. The immunomodulatory role of LIF in cancer"
25th Biennial Congress of the European Association for Cancer Research (EACR)
RAI Convention Centre
Amsterdam, The Netherlands | 1st July 2018

"General Conclusions & Award Presentation"
LIF As We Know It: From Basic Science to Clinical Trials
Chair & Scientific Organizer
VHIO (Vall d'Hebron Institute of Oncology)
Barcelona, Spain | 29th May 2018

"Immunomodulatory role of LIF in cancer"
LIF As We Know It: From Basic Science to Clinical Trials
Chair & Scientific Organizer
VHIO (Vall d'Hebron Institute of Oncology)
Barcelona, Spain | 28th May 2018

"La complejidad de la vida. El cáncer."
Pint Of Science Festival
Barcelona, Spain | 15th May 2018

"The role of CDK along the mitotic process in normal and pathological condition"
Co-Chair: ESMO Symposium on Signalling Pathways in Cancer 2018
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain | 23rd March 2018

"Implicaciones de la evolución de la heterogeneidad genética intratumoral en el tratamiento del cáncer"
IV Simposio Nacional de Genómica Aplicada en Oncología
CNIO (Centro Nacional de Investigaciones Oncológicas)
Madrid, España | 20th March 2018

2017

"Is there a role for targeting transforming growth-factor-b?"
ESMO Immuno-oncology Congress 2017
Palexpo
Geneva, Switzerland | 10th December 2017

"NGS y LCR: presente y futuro"
IX Symposium GEINO 2017
Universidad de Málaga
Málaga, Spain | 30th November 2017

"Molecular insights to glioblastoma progression and therapy resistance"
1st ASEICA Educational Symposium
Facultad de Medicina, Universidad Autónoma de Madrid (UAM)
Madrid, Spain | 14th November 2017

"Novel therapeutic targets in brain tumors"
Defence is the Best Attack. Immuno-Oncology Breakthroughs
EACR Conference Series

La Pedrera
Barcelona, Spain | 9th October 2017

"What can we learn from patient-derived models?"
Special Symposium: Targeted therapy in neuro-oncology
ESMO 2017
IFEMA
Madrid, Spain | 10th September 2017

- *Translational Research: Proffered paper & Poster discussion*
Chair & Invited Lecturer
ESMO 2017
IFEMA
Madrid, Spain | 9th September 2017
- *"Oncology and research in Spain and beyond: Sharing knowledge about cancer"*
Special Event: AECC, ASEICA, EACR, ESMO and SEOM
Invited Lecturer
El Prado Museum Auditorium
Madrid, Spain | 7th September 2017
- *"The TGF- β signaling in glioblastoma"*
FASEB TGF-beta Conference
Marriot Hotel
Lisbon, Portugal | 11th July 2017
- *"Utilidad de la biopsia líquida en el diagnóstico del Glioblastoma y de las metástasis cerebrales"*
Curso de Neuropatología. Avances en Patología Molecular e Inmunooncología en Neuropatología.
XXVIII Congreso Nacional SEAP-IAP
Palacio de Congresos de Valencia
Valencia, Spain | 26th May 2017
- *"El conocimiento molecular del cáncer. Modelos animales"*
Jornadas Iberoamericanas sobre cáncer de mama metastásico.
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain | 15th May 2017
- *"Fighting cancer. Defeating an heterogeneous and changing enemy"*
Inaugural conference.
Institut de Biotecnologia i de Biomedicina.
Barcelona, Spain | 9th May 2017
- *"Genomic intratumor heterogeneity and cancer resistance to treatment"*
ICREA-FIJC 2017 Meeting
Auditorium of the School of Medicine. University of Barcelona.
Barcelona, España | 7th March 2017
- *"Evolving intratumor heterogeneity in primary and secondary brain malignancies"*
CNIO Frontiers Meeting: "Primary and Secondary Brain Tumors"
CNIO (Centro Nacional de Investigaciones Oncológicas)
Madrid, España | 21st February 2017
- *"Evolving intratumor heterogeneity in brain tumors"*
Symposium 5 - Distinguished Spanish speakers session
Human Genome Meeting 2017
Hotel Barceló Sants

Barcelona, España | 6th february 2017

2016

- *“Biopsia líquida”*
Heterogeneidad Tumoral: Implicaciones Clínicas en Glioblastomas.
VIII Symposium Educacional GEINO 2016: Tratamiento de los Tumores Cerebrales
Hospital Universitario Ramón y Cajal
Madrid, España | 25th November 2016
- *“Detección de marcadores moleculares circulantes en biopsia líquida en el glioblastoma”*
La Neuropatología y Nuevas Tecnologías
LXVIII Reunión Anual de la Sociedad Española de Neurología
Palacio de Congresos de Valencia
Valencia, España | 18th November 2016
- *“Intratumor heterogeneity in cancer”*
II Reunión de Investigación Traslacional en Melanoma
Hospital Universitario Quirón Dexeus
Barcelona, España | 3rd November 2016
- *Intratumor Heterogeneity*
Cancer Immunotherapy
NCT SummerSchool in Translational Cancer Research
DKTK German Cancer Consortium
Hotel Porto Bay Falesia
Albufeira, Portugal | 28th October 2016
- *“Preclinical concepts of glioma”*
XII Meeting of the European Association of Neuro-Oncology (EANO) and Educational Day
Congress Center Rosengarten
Mannheim, Germany | 13th October 2016
- *Translational research*
Chair - Poster session
ESMO 2016 Congress
Bella Center Copenhagen Convention Center
Copenhaguen, Denmark | 10th October 2016
- *Patient derived models to select treatment*
Conclusions and clinical perspectives
Special Symposium: Using biomarkers to monitor the dynamics of tumor responses to therapy
Chair & Speaker
ESMO 2016 Congress
Bella Center Copenhagen Convention Center
Copenhaguen, Denmark | 10th October 2016
- *Conclusions and Clinical Perspectives*
Special Session: Will we ever conquer resistance?
Co-Chair & Speaker
ESMO 2016 Congress
Bella Center Copenhagen Convention Center
Copenhaguen, Denmark | 8th October 2016
- *Basic science and translational research*
Chair & Discussant: Poster session
ESMO 2016 Congress

Bella Center Copenhagen Convention Center
Copenhagen, Denmark | 8th October 2016

- *"New therapeutic targets in glioblastoma"*
Novel targeted therapies
24th Biennial Congress of the European Association for Cancer Research
Manchester Central Convention Complex
Manchester, UK | 11th July 2016
- *"Glioblastoma microenvironment"*
Brain Tumors 2016 from Biology to Therapy
Nencki Institute of Experimental Biology
Warsaw, Poland | 27th June 2016
- *"Biomarkers of response to anti-TGF-beta agents in cancer".*
IT-LIVER Final Conference: "TGF-beta family in fibrosis and cancer"
IT-LIVER EU (Marie Curie 7th Framework Program)
Barcelona, Spain | 14th June 2016
- *"Evolving Intratumor Genomic Heterogeneity in Brain Cancer"*
EMBO Meeting Cellular signaling and Cancer therapy
Cavtat, Dubrovnik, Croatia | 29th May 2016
- *"Intratumor Heterogeneity and Clonal Evolution in Glioblastoma"*
VHIO Symposium: Towards Predictive Cancer Models
Barcelona, Spain | 26th May 2016
- *"Evolving intratumor genomic heterogeneity in brain cancer"*
Personalized Cancer Care meeting
Institute for Cancer Research
Oslo University Hospital
Oslo, Norway | 19th May 2016
- *"III Jornada Recerca i Empresa: Converses en Feedwork"*
Universitat de Barcelona (UB), Facultat de Psicologia
Recerca, Salut i Innovació"
Barcelona, Spain | 3rd May 2016
- *"Fighting cancer. How to defeat a multifaceted, fluctuating and partially unknown enemy"*
Master class.
Universitat de Vic (UViC)
Vic, Barcelona, Spain | 20th April 2016
- *"Inmunoterapia en glioblastoma"*
Preceptorship Inmunooncología
UITM & MSD: Conceptos actuales de Inmunooncología Clínica y Traslacional
Auditorium Cellex.
Barcelona, Spain | 15th -16th February 2016
- *"Patient-derived xenograft models in glioblastoma "*
Chair & Speaker
AACR Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic
conference.
Hyatt Regency New Orleans
New Orleans, Louisiana | 13th February 2016

- *Plenary Session 5: Disease-specific PDX Models III*
Chair
AACR Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic conference.
Hyatt Regency New Orleans
New Orleans, Louisiana | 13th February 2016

2015

- *"Cancer initiating cells in brain tumors"*
8th Biennial Congress of the SETGyC
Kursaal Congress Center
San Sebastián, Spain | 5th November 2015
- *"El valor de la innovación en oncología"*
XV Congreso SEOM
Hotel Melia Castilla
Madrid, Spain | 28th October 2015
- *"Research and development for brain tumour treatments – Thinking Outside the Box"*
IBTA - Second World Summit of Brain Tumour Patient Advocates
Meliá Sitges Hotel
Sitges, Barcelona, Spain | 27th October 2015
- *"The TGF- β pathway as a therapeutic target against cancer"*
15th ASEICA International Congress
Sevilla, Spain | 22nd October 2015
- *"Tumor cell heterogeneity"*
3rd EurocanPlatform Summer School in Translational Cancer Research
Hotel Porto Bay
Falesia, Portugal | 14th October 2015
- *"TGF β and immunoresistance"*
Ponencia. 1^a Reunión Investigación Translacional en Melanoma
Hospital Universitario Quirón Dexeus
Barcelona | 2nd October 2015
- *"Biological and clinical impact of intratumor heterogeneity"*
15th Anniversary Cancer Research Center
CSIC University of Salamanca
Salamanca, Spain | 1st October 2015
- *"Impact of intratumor heterogeneity in glioblastoma relapse"*
European CanCer Organisation (ECCO) Congress
Society Session: Clinical and Biological Implications of Intratumor Heterogeneity
Vienna, Austria | 26th September 2015
- *"Evolution of the intratumor heterogeneity in glioblastoma in response to treatment"*
II International Symposium on Clinical and Basic Investigation on Glioblastoma
Plenary Session
Universidad de Castilla – La Mancha. Campus de Toledo
Toledo, España | 10th September 2015
- *"Impact of the intratumor genomic heterogeneity and evolution in the treatment of glioblastoma"*
2nd EACR Special Conference on Cancer Genomics

Session 3: Genomic Mechanisms of Resistance
Churchill College, University of Cambridge
Cambridge, UK | 30th June 2015

- *"ctDNA in CSF, characterization in brain tumors"*
Workshop on Circulating Biomarkers in Cancer
Circulating cancer biomarkers: Technical session
EurocanPlatform
Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital
Oslo, Norway | 18th May 2015
- *"Molecular mechanisms involved in glioblastoma"*
Guest Speaker Seminar
Cancer Research UK, Manchester Institute, The University of Manchester
Manchester, UK | 29th January 2015
- *"Intratumor heterogeneity in brain tumors"*
Cell Communication in Translational Research
Weizmann Institute of Science-Vall d'Hebron Institute of Oncology Conference
The David Lopatie Conference Centre, Weizmann Institute of Science
Rehovot, Israel | 22nd January 2015

2014

- *"Hacia una nueva comprensión del cáncer y sus terapias"*
Ciclo de debates y conferencias "Células madre: ¿un futuro sin enfermedades?"
Centre de Cultura Contemporània de Barcelona (CCCB)
Barcelona, Spain | November 2014
- *"La vía del TGF- β como diana terapéutica contra el cáncer"*
IV Ciclo Seminarios de Investigación (2014-15)
Facultad de Medicina y Gerencia de Atención Integrada de Ciudad Real
Ciudad Real, Spain | November 2014
- *"FoxG1 confers resistance to PI3K inhibitors"*
Annual Meeting - PI3K: Paper en Fisiologia i Patologia
Societat Catalana de Biologia
Barcelona, Spain | October 2014
- *"The TGF- β pathway as a therapeutic target"*
23rd Biennial Congress of the European Association for Cancer Research (EACR)
International Congress Centre Munich (ICM)
Munich, Germany | 7th July 2014
- *"TGF- β : A Prime Target for Cancer Immunotherapy"*
12th CIMT Annual Meeting - The Association for Cancer Immunotherapy
Rheingoldhalle Main Congress Center
Mainz, Germany | 7th May 2014
- *"The TGF- β pathway as a therapeutic target in brain tumors"*
Karolinska Institutet Stockholm
Stockholm, Sweden | April 2014
- *"Intratumoral heterogeneity in glioblastoma"*
AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment
The Westin Gaslamp Quarter
San Diego, CA, USA | February-March 2014

- *"Targeting the TGF- β pathway in brain tumors"*
Biotech Research and Innovation Center (BRIC)
University of Copenhagen
Copenhagen, Denmark | *January 2014*

2013

- *"The TGF- β pathway as a therapeutic target in brain tumors"*
Stem Cells and Regenerative, Medicine Seminar Series
An Interdisciplinary Approach to Stem Cell Science
Faculty of Medicine, University of Geneva
Geneva, Switzerland | *November 2013*
- *"Intra-Tumoral Heterogeneity in Brain Tumors"*
17th Fritz Bender Foundation International Symposium: Progreso Hacia el Tratamiento Individualizado del Cáncer
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain | *November 2013*
- *"The TGF- β pathway as a therapeutic target"*
IT LIVER Workshop: "Omics meet translational research"
Marie-Curie ITN action "ITLiver"
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) - Societat Catalana de Biologia (SCB)
Barcelona, Spain | *September 2013*
- *"Tumor Initiating Cell Population in Human Glioblastoma"*
10th JIM Key Symposium: Taming the Cancer Cell
Journal of Internal Medicine - Royal Swedish Academy of Science
Stockholm, Sweden | *September 2013*
- *"Targeting TGF- β in glioblastoma"*
Conference TGF- β Superfamily: Signaling in Development and Disease
Federation of American Societies for Experimental Biology (FASEB)
Colorado, USA | *July 2013*
- *"TGF- β y gliomas"*
Centro Nacional de Investigaciones Oncológicas (CNIO)
Madrid, Spain | *July 2013*
- *"Mecanismos Moleculares del Cáncer"*
Curso de Formación de Ensayos Clínicos en Oncología
Vall d' Hebron University Hospital
Barcelona, Spain | *July 2013*
- *"Heterogeneidad intratumoral en glioblastoma"*
XI Ciclo de Seminarios
Instituto de Biomedicina de Sevilla (IBIS)
Hospital Universitario Virgen del Rocío
Sevilla, Spain | *June 2013*
- *"Amilogénesis y cáncer"*
Breast Cancer Management Course
Vall d'Hebron Institute of Oncology (VHIO)
Vall d' Hebron University Hospital
Barcelona, Spain | *June 2013*

- *"Intratumoral heterogeneity in glioblastoma"*
Hospital Universitario Madrid Sanchinarro
Madrid, Spain | June 2013
- *"The TGF- β pathway as a therapeutic target in cancer"*
Centro de Investigaciones Biológicas (CIB)
Madrid, Spain | May 2013
- *"Modelling the behaviour of cancer stem cells"*
5th Symposium on Anticancer Drug Discovery
Pre-clinical models of cancer: Towards enhanced clinical relevance and predictivity
Oncotest Institute for Experimental Oncology
Freiburg, Germany | April 2013
- *"Functional analysis with patient-derived models. Getting close to the real tumor"*
XXI Porto Cancer Meeting
Auditorium of IPATIMUP (Institute of Molecular Pathology and Immunology of the University of Porto)
Porto, Portugal | April 2013
- *"Cancer Stem Cells/Cancer-Initiating Cells: Signaling and Treatment Approaches"*
AACR Annual Meeting
Walter E. Washington Convention Center
Washington DC, USA | April 2013
- *"The Transforming growth factor β as a therapeutic target in glioblastoma"*
EORTC-EANO-ESMO Conference 2013
Clarion Congress Hotel
Prague, Czech Republic | March 2013

2012

- *"Regulation of the cell state of differentiation by TGF- β "*
"Chromosomes, Stem Cells and Disease" Annual Meeting
Parc de Recerca Biomèdica de Barcelona (PRBB)
Barcelona, Spain | September 2012
- *"Molecular Mechanisms of gliomagénesis"*
Satellite event, FENS Forum 2012: Developmental Tumors of the Nervous System
Hospital Sant Joan de Déu
Barcelona, Spain | July 2012
- *"Translational research in glioblastoma: linking molecular characterization to treatment"*
"Translating cancer research to personalized hospital treatment. Can it work?"
"Cancer-initiating Cells in Glioblastoma"
EARC22 - European Association for Cancer Research
Barcelona, Spain | July 2012
- *"Intra-tumoral heterogeneity in Glioblastoma"*
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Barcelona, Spain | June 2012
- *"Angiogenesis en càncer de mama"*
Course: "Anticuerpos Monoclonales en Càncer de Mama. Optimizando estudios clínicos y sus resultados"
Vall d' Hebron University Hospital
Barcelona, Spain | March 2012

- *"Expressió gènica i biologia del càncer"*
Vall d' Hebron University Hospital
Barcelona, Spain | *March 2012*
- *"TGF- β y gliomas"*
Centro Nacional de Investigaciones Oncológicas (CNIO)
Madrid, Spain | *May 2012*
- *"Cancer-initiating cells in glioblastoma"*
Cabimer - Centro Andaluz de Biología Molecular y Medicina Regenerativa
Sevilla, Spain | *March 2012*
- *"Signalling pathways of cancer stem cells and molecular diagnosis of glioblastoma. Update and therapeutic implications"*
VIII Jornada de Neuro-Oncología: El Glioblastoma
Barcelona, Spain | *February 2012*

2011

- *"Etiología y Tratamiento de los Tumores Cerebrales"*
Curso de Neurociencia
Institut de Recerca Biomèdica de Lleida
Lleida, España | *November 2011*
- *"The cancer stem cell niche"*
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
San Francisco, USA | *November 2011*
- *"TGF- β and Cancer-Initiating Cells. Targeting the root of cancer"*
XIII Congreso Nacional ASEICA
Salamanca, Spain | *September 2011*
- *"TGF- β as a therapeutic target in glioblastoma. Targeting glioma-initiating cells"*
International Symposium on Clinical & Basic Investigation in Glioblastoma
Valencia, Spain | *June 2011*
- *"Tumor-initiating cells in glioblastoma. Targeting the root of cancer"*
Brain Tumor Meeting 2011
MDC - Molecular Medicine Berlin-Buch
Berlin, Germany | *June 2011*
- *"Targeting signaling pathways that mediate cancer stem cell survival"*
ASCO Annual meeting 2011
Chicago, USA | *June 2011*
- *"Células iniciadoras de tumor en glioma"*
I Jornadas de actualización en Mecanismos Moleculares del Cáncer
Red Temática de Investigación Cooperativa en Cáncer (RTICC)
Santander, Spain | *May 2011*
- *"Células iniciadoras de cáncer como dianas terapéuticas en gliomas"*
Simposio Internacional de Oncología Traslacional - WTC
Barcelona, Spain | *May 2011*

- *“Células madre tumorales como diana terapéutica”*
Simposio de Investigación y Terapia con células madre: avances y realidades
Academia Médico-Quirúrgica de Santiago de Compostela
Santiago de Compostela, Spain | *March 2011*
- *“Apoptosis, tumor involution and potenciales for stem cells”*
Education Committee of the European Society of Neurology - ECNR
European Board of Neuroradiology (EBNR)
Roma, Italy | *March 2011*
- *“TGF- β y gliomas”*
Centro Nacional de Investigaciones Oncológicas (CNIO)
Madrid, Spain | *March 2011*
- *“TGF- β and cancer initiating cells. Targeting the root of cancer”*
Parc de Recerca Biomèdica de Barcelona (PRBB)
Barcelona, Spain | *February 2011*

2010

- *“Effect of TGF- β on cancer initiating cells”*
Oncobio 2010. Cancer, stem cells and metastasis
Salamanca, Spain | *November 2010*
- *“Espacio de la radioterapia en el nuevo desarrollo de los fármacos para el tratamiento de tumores cerebrales”*
Grupo de Investigación Clínica en Oncología Radioterápica (GICOR)
Madrid, Spain | *November 2010*
- *“TGF- β y gliomas”*
Centro Nacional de Investigaciones Oncológicas (CNIO)
Madrid, November | *Spain 2010*
- *“FoxG1 is a functional repressor of FoxO in glioblastoma and affects the anti-tumoral activity of PI3K inhibitors”*
IRB Metabolism
Barcelona, Spain | *November 2010*
- *“The TGF- β pathway in glioma and tumor-initiating cells”*
Danish Cancer Society
Copenhagen, Denmark | *October 2010*
- *“The effect of TGF- β on glioma and glioma-initiating cells”*
Centro de Investigación Príncipe Felipe
Valencia, Spain | *September 2010*
- *“The role of TGF- β in glioma genesis and progression”*
7th FENS Forum of European Neuroscience
RAI Convention Centre
Amsterdam, The Netherlands | *July 2010*
- *“The effect of TGF- β on glioma initiating cells”*
EACR 21 - European Association for Cancer Research
Norway Exhibition & Convention Centre
Oslo, Norway | *June 2010*

- Seminarios *Científicos*
Centro de Investigación del Cáncer (CIC-IBMCC)
Salamanca, Spain | *February 2010*

2009

- *"Efecto del TGF- β en células madre del cáncer"*
Facultad de Ciencias y Tecnología
Bilbao, Spain
- *"La Vía del TGF- β como Diana terapéutica en glioma"*
Centro Nacional de Microbiología
Instituto de Salud Carlos III
Madrid, Spain
- *"Papel del TGF- β en el tumor cerebral"*
Unidad de Cristalografía de Macromoléculas
Instituto de Biomedicina de Valencia (CSIC)
Valencia, Spain
- *"TGF- β and cancer"*
Center for Genomic Regulation (CRG)
Barcelona, Spain
- *"Mecanismos de regulación de las células madre de glioma"*
Universidad de Santiago de Compostela
Santiago de Compostela, Spain
- *"TGF- β and cancer"*
XII Congreso Nacional ASEICA
Madrid, Spain

2008

- *"Glioma initiating cells"*
Karolinska Stem Cell Meeting
Stockholm, Sweden
- *"TGF- β in brain tumors"*
European Association for Neuro-Oncology (EANO)
Barcelona, Spain
- *"The role of TGF- β in glioma"*
EACR 20 - European Association for Cancer Research
Lyon, France
- *"The oncogenic role of TGF- β in glioma"*
Keystone Symposia on Molecular and Cellular Biology
Santa Fe, NM, USA

2007

- *"The role of TGF- β in oncogenesis"*
Center for Genomic Regulation (CRG)
Barcelona, Spain

- *"The dark side of TGF- β in glioma"*
Asociación española de Investigación sobre el cáncer. ASEICA 2007
Las Palmas de Gran Canaria, Spain
- *"Oncogenic role of the TGF- β pathway in glioma"*
Nederland Cancer Institute seminars
Amsterdam, The Netherlands
- *"The role of TGF- β in oncogenesis"*
TGF- β Meeting, Ludwig Institute
Uppsala, Sweden
- *"The role of TGF- β in oncogenesis"*
Brain Cancer Initiative Meeting, Ludwig Institute.
New York, USA
- *"TGF- β in oncogenesis"*
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)
Barcelona, Spain
- *"The role of TGF- β in oncogenesis"*
European Association for Cancer Research Symposium
British Association for Cancer Research
Nottingham, UK

2006

- *"Oncogenic role of the TGF- β pathway in glioma"*
I Meeting on Cell Proliferation and Cancer
Mallorca, Spain
- *"The TGF- β oncogenic response in glioma"*
31st European Symposium on Hormones and Cell Regulation
Mont-Sainte-Odile, France

2005

- *"Las dos caras del TGF- β en oncogénesis"*
Sociedad Española de Biología Celular XI Annual Symposium
Cádiz, Spain
- *"The role TGF- β in oncogenesis"*
Centro Nacional de Investigaciones Oncológicas (CNIO)
Madrid, Spain
- *"TGF- β inhibitors"*
Federation of European Cancer Societies
European Cancer Conference - ECCO 13
Paris, France
- *"TGF- β and Cancer"*
International Symposium SFB 518
Ulm, Germany
- *"Papel del TGF- β en oncogénesis. Aproximación mediante análisis de microarrays de DNA"*

2004

- *“Role of TGF- β in oncogenesis”*
3rd Annual Symposium on Anti-Signaling Strategies in Human Neoplasia
Barcelona, Spain
- *“Papel del TGF- β en glioma”*
Tumores del sistema nervioso central: Investigación y Clínica
Centro Nacional de Investigaciones Oncológicas (CNIO)
Madrid, Spain
- *“Paper del TGF- β en oncogenesis”*
Seminari Universitat de Barcelona, Departament de Bioquímica, Campus Bellvitge
Barcelona, Spain
- *“Papel del TGF- β en progresión tumoral. Las dos caras del TGF- β ”*
Seminario Instituto de Investigación Biomédica
Madrid, Spain
- *“Curso animales modificados genéticamente: presente y futuro en la investigación biomédica”*
Curso de Verano, Universidad de Santiago de Compostela
Santiago de Compostela, Spain
- *“Integración de las vías del TGF- β y PI3K-AKT en cancer. Papel de FoxG1”*
Sociedad Española de Bioquímica y Biología Molecular (SEBBM) XXVII Annual Symposium
Lleida, Spain
- *“Dissecting signal transduction pathways in tumorogenesis using microarray analysis”*
Workshop on Biomedical Genomics and Proteomics
Red Temática de Genómica y Proteómica (Generalitat- DURSI) y Red de Centros de Oncología (Nodo Vall d'Hebron)
Conference Room, Vall d'Hebron University Hospital
Barcelona, Spain | 10 May 2004
- *“Mecanismos de la inhibición de la proliferación celular por TGF- β . Relevancia en Oncogénesis”*
Seminar, Centro de Investigación del Cáncer – Instituto de Biología Molecular y Celular del Cáncer (CIC-IBMCC)
Salamanca, Spain
- *“Mechanisms of TGF- β -mediated inhibition of cell proliferation. Relevance in oncogenesis”*
Seminar, Centre for Genomic Regulation (CRG)
Barcelona, Spain
- *“Integration of Smad, FoxO and FoxG1 pathways in the TGF- β cytostatic program”*
EMBL/Salk/EMBO Conference on Oncogenes and Growth Control
Heidelberg, Germany
- *“The TGF- β cytostatic program. Integration of Smad, Myc, PI3K and Forkhead pathways”*
Keystone Symposia on Molecular and Cellular Biology
Cell Cycle and Development
Snowbird, Utah, USA

